[1] LI Y Z, TENG D, BA J M, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: Epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4):568-579.
[2] LAURBERG P, CERQUEIRA C, OVESEN L, et al. Iodine intake as a determinant of thyroid disorders in populations[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(1):13-27.
[3] SIGFUSSON N, IVERSEN E, KNUDSEN P R. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark[J]. J Clin Endocrinol Metab, 1998, 83(3):765-769.
[4] BOELAERT K. Thyroid dysfunction in the elderly[J]. Nat Rev Endocrinol, 2013, 9(4):194-204.
[5] NORDYKE R A, GILBERT F I Jr, HARADA A S. Graves’ disease. Influence of age on clinical findings[J]. Arch Intern Med, 1988, 148(3):626-631.
[6] BOELAERT K, TORLINSKA B, HOLDER R L, et al. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study[J]. J Clin Endocrinol Metab, 2010, 95(6):2715-2726.
[7] LILLEVANG-JOHANSEN M, ABRAHAMSEN B, JORGENSEN H L, et al. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk[J]. Thyroid, 2019, 29(3):332-340.
[8] FROST L, VESTERGAARD P, MOSEKILDE L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study[J]. Arch Intern Med, 2004, 164(15):1675-1678.
[9] GAN E H, PEARCE S H. Clinical review: The thyroid in mind: cognitive function and low thyrotropin in older people[J]. J Clin Endocrinol Metab, 2012, 97(10):3438-3449.
[10] BAUER D C, ETTINGER B, NEVITT M C, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone[J]. Ann Intern Med, 2001, 134(7):561-568.
[11] SATOH T, ISOZAKI O, SUZUKI A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition)[J]. Endocr J, 2016, 63(12):1025-1064.
[12] ZHAI X D, ZHANG L, CHEN L L, et al. An age-specific serum thyrotropin reference range for the diagnosis of thyroid diseases in older adults: a cross-sectional survey in China[J]. Thyroid, 2018, 28(12): 1571-1579.
[13] SHI H, SHENG R, HU Y, et al. Risk factors for the relapse of Graves’ disease treated with antithyroid drugs: a systematic review and meta-analysis[J]. Clin Ther, 2020, 42(4):662-675.e4.
[14] KIM Y A, CHO S W, CHOI H S, et al. The second antithyroid drug treatment is effective in relapsed Graves’ disease patients: a median 11-year follow-up study[J]. Thyroid, 2017, 27(4):491-496.
[15] TAKÁTS K I, SZABOLCS I, FÖLDES J, et al. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses[J]. Exp Clin Endocrinol Diabetes, 1999, 107(1):70-74.
[16] NAKAMURA H, MIYAUCHI A, MIYAWAKI N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan[J]. J Clin Endocrinol Metab, 2013, 98(12):4776-4783.
[17] Pearce S H. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK[J]. Clin Endocrinol: Oxf, 2004, 61(5):589-594.
[18] WANG M T, LEE W J, HUANG T Y, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study[J]. Br J Clin Pharmacol, 2014, 78(3): 619-629. |
